• English
  • 简体中文
Login Register
Current Location: Home > Feedback Help Print

【结 构 式】

【药物名称】RXP-407

【化学名称】3(S)-Acetamido-4-[N-[1(R)-[[3-[1(S)-carbamoylethylamino]-2(S)-methyl-3-oxopropyl](hydroxy)phosphoryl]-2-phenylethyl]amino]-4-oxobutyric acid

【CA登记号】237770-41-1, 237770-43-3 (diastereomer), 237770-42-2 (diastereomeric mixture), 237770-44-4 (diastereomeric mixture)

【 分 子 式 】C21H31N4O8P

【 分 子 量 】498.47702

【开发单位】INSERM (Originator)

【药理作用】Chemoprotective Agents, ONCOLYTIC DRUGS, Radioprotectants

合成路线1

Protection of the hydroxyphosphinyl function of Z-Phe(PO2)H (I) by treatment with AgNO3 and 1-adamantyl bromide (AdBr) affords protected compound (II). Treatment of (II) with ethyl methylacrylate (III) by means of hexamethyldisilazane provides compound (IV), which is then subjected to saponification with NaOH in EtOH, affording carboxylic acid (V). The Z protecting group of (V) is then removed with Pd/C and ammonium formate, and subsequent reaction with FmocCl in dioxane yields protected derivative (VI). Separately, on resin protected alanine (VII) is treated with piperidine/NMP for Fmoc removal to afford (VIII), which is then coupled with phosphinic derivative (VI) by means of HBTU/DIEA in NMP and then treated with piperidine/NMP for Fmoc removal, giving derivative (IX). Coupling between (IX) and FmocAsp(OtBu)OH by means of HBTU and DIEA in NMP followed by Fmoc removal with piperidine/NMP affords phosphinic peptide (X), which is then acetylated to give derivative (XI). Finally, the desired product is obtained after first treatment of (XI) with HOAc and trifluoroethanol (TFE) in CH2Cl2 for cleavage of the protected peptide from the resin, followed by removal of the protecting groups with TFA and scavengers (thioanisole, phenol, ethanedithiol and triisopropylsilane) in CH2Cl2/H2O and final separation of the diastereoisomeric forms of the resulting phosphinic peptides by HPLC.

1 Yiotakis, A.; et al.; Protection of the hydroxyphosphinyl function of phosphinic dipeptides by adamantyl. Application to the solid-phase synthesis of phosphinic peptides. J Org Chem 1996, 61, 19, 6601.
2 Yiotakis, A.; Menard, J.; Dive, V.; Michaud, A.; Ezan, E.; Corvol, P.; Cotton, J.; Chauvet, M.-T.; Cuniasse, P. (Commissariat a l'Energie Atomique; INSERM (Institut National de la Sante et de la Recherche Medicale)); N-Terminal site selective inhibitors of human angiotensin conversion enzyme (ACE). EP 1091966; WO 0001706 .
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(A) 22260 (2S)-4-(tert-butoxy)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-oxobutyric acid C23H25NO6 详情 详情
(I) 49739 (1R)-1-[[(benzyloxy)carbonyl]amino]-2-phenylethylphosphinic acid C16H18NO4P 详情 详情
(II) 49740 1-adamantyl (1R)-1-[[(benzyloxy)carbonyl]amino]-2-phenylethylphosphinate C26H32NO4P 详情 详情
(III) 49741 Methacrylic acid ethyl ester; Ethyl methacrylate 97-63-2 C6H10O2 详情 详情
(IV) 49742 ethyl (2S)-3-[(1-adamantyloxy)((1R)-1-[[(benzyloxy)carbonyl]amino]-2-phenylethyl)phosphoryl]-2-methylpropanoate C32H42NO6P 详情 详情
(V) 49743 (2S)-3-[(1-adamantyloxy)((1R)-1-[[(benzyloxy)carbonyl]amino]-2-phenylethyl)phosphoryl]-2-methylpropionic acid C30H38NO6P 详情 详情
(VI) 49744 (2S)-3-[(1-adamantyloxy)((1R)-1-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-2-phenylethyl)phosphoryl]-2-methylpropionic acid C37H42NO6P 详情 详情
(VII) 49745 9H-fluoren-9-ylmethyl (1S)-2-amino-1-methyl-2-oxoethylcarbamate C18H18N2O3 详情 详情
(VIII) 35169 (2S)-2-aminopropanamide C3H8N2O 详情 详情
(IX) 49746 1-adamantyl (2S)-3-[[(1S)-2-amino-1-methyl-2-oxoethyl]amino]-2-methyl-3-oxopropyl[(1R)-1-amino-2-phenylethyl]phosphinate C25H38N3O4P 详情 详情
(X) 49747 tert-butyl (3S)-4-([(1R)-1-[(1-adamantyloxy)((2S)-3-[[(1S)-2-amino-1-methyl-2-oxoethyl]amino]-2-methyl-3-oxopropyl)phosphoryl]-2-phenylethyl]amino)-3-amino-4-oxobutanoate C33H51N4O7P 详情 详情
(XI) 49748 tert-butyl (3S)-3-(acetamido)-4-([(1R)-1-[(1-adamantyloxy)((2S)-3-[[(1S)-2-amino-1-methyl-2-oxoethyl]amino]-2-methyl-3-oxopropyl)phosphoryl]-2-phenylethyl]amino)-4-oxobutanoate C35H53N4O8P 详情 详情
Extended Information